DE602004009169D1 - Verwendung von Cyanin-farbstoffen zur Diagnose von Krankheiten, welche mit Angiogenese assoziert sind - Google Patents

Verwendung von Cyanin-farbstoffen zur Diagnose von Krankheiten, welche mit Angiogenese assoziert sind

Info

Publication number
DE602004009169D1
DE602004009169D1 DE602004009169T DE602004009169T DE602004009169D1 DE 602004009169 D1 DE602004009169 D1 DE 602004009169D1 DE 602004009169 T DE602004009169 T DE 602004009169T DE 602004009169 T DE602004009169 T DE 602004009169T DE 602004009169 D1 DE602004009169 D1 DE 602004009169D1
Authority
DE
Germany
Prior art keywords
angiogenesis
diagnosis
diseases associated
cyanine dyes
cyanine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004009169T
Other languages
English (en)
Inventor
Michael Schirner
Kai Licha
Peter Hauff
Christin Perlitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Schering Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma AG filed Critical Bayer Schering Pharma AG
Publication of DE602004009169D1 publication Critical patent/DE602004009169D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
DE602004009169T 2004-07-22 2004-07-22 Verwendung von Cyanin-farbstoffen zur Diagnose von Krankheiten, welche mit Angiogenese assoziert sind Active DE602004009169D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04017375A EP1619501B1 (de) 2004-07-22 2004-07-22 Verwendung von Cyanin-farbstoffen zur Diagnose von Krankheiten, welche mit Angiogenese assoziert sind

Publications (1)

Publication Number Publication Date
DE602004009169D1 true DE602004009169D1 (de) 2007-11-08

Family

ID=34925879

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004009169T Active DE602004009169D1 (de) 2004-07-22 2004-07-22 Verwendung von Cyanin-farbstoffen zur Diagnose von Krankheiten, welche mit Angiogenese assoziert sind

Country Status (15)

Country Link
EP (3) EP1619501B1 (de)
JP (1) JP2008506747A (de)
KR (1) KR20070062973A (de)
CN (1) CN101022835A (de)
AR (1) AR050264A1 (de)
AT (1) ATE374367T1 (de)
AU (1) AU2005263638A1 (de)
CA (1) CA2573783A1 (de)
DE (1) DE602004009169D1 (de)
PA (1) PA8640201A1 (de)
PE (1) PE20060558A1 (de)
SV (1) SV2006002172A (de)
TW (1) TW200613733A (de)
UY (1) UY29029A1 (de)
WO (1) WO2006008179A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1679082A1 (de) * 2005-01-07 2006-07-12 Schering AG Benutzung von Cyaninfarbstoffen für die Diagnose von proliferierenden Krankheiten
EP1745739A3 (de) * 2005-07-14 2009-04-22 Bundesrepublik Deutschland, vertr. d.d. Bundes- ministerium f. Wirtschaft- und Technologie, dieses vertr. d.d. Präs. d. Phys.-Techn. Bundesanstalt Optische Darstellung von rheumatischer Arthritis
DE102007037008B4 (de) * 2007-08-06 2015-09-10 Siemens Aktiengesellschaft Diagnosesubstanz zur Anwendung in einem Verfahren zur Bestimmung der Aggressivität eines Prostatatumors
DE102007038730A1 (de) * 2007-08-16 2009-02-19 Carl Zeiss Meditec Ag Nachweis des menschlichen Vascular Endothelial Growth Factor
US9097667B2 (en) 2007-12-14 2015-08-04 Biotium, Inc. Fluorescent compounds
WO2009103312A1 (en) * 2008-02-19 2009-08-27 Ludwig-Maximilians-Universität Ezrin, serpin b5, peroxiredoxin-2 and heat shock protein beta-1 as autoantigens for psoriasis and poststreptococcal diseases
CN101518528B (zh) * 2008-02-29 2014-02-26 史春梦 一组碳花青染料类的近红外荧光化合物的用途
US9186336B2 (en) 2009-02-06 2015-11-17 The General Hospital Corporation Methods of treating vascular lesions
CN102481380A (zh) * 2009-07-09 2012-05-30 霍夫曼-拉罗奇有限公司 体内肿瘤血管系统成像
US8658434B2 (en) 2009-10-28 2014-02-25 Biotium, Inc. Fluorescent pyrene compounds
GB0922014D0 (en) 2009-12-17 2010-02-03 Ge Healthcare Ltd Novel integrin binders
WO2014122228A1 (en) 2013-02-07 2014-08-14 Westfaelische Wilhelms-Universitaet Muenster Labelled compounds that bind to alpha-v-beta-3 integrin
JP6752582B2 (ja) * 2016-02-08 2020-09-09 キヤノン株式会社 光音響イメージング用造影剤
TWI617281B (zh) * 2017-01-12 2018-03-11 財團法人工業技術研究院 傷口狀態分析方法與系統
CN108410202A (zh) * 2018-02-12 2018-08-17 成都驷博生物科技有限公司 一种喹啉七甲川菁染料的制备方法
CN110201189B (zh) * 2019-06-03 2021-12-07 沈阳药科大学 白蛋白结合型近红外荧光染料-马来酰亚胺共轭物
CN112994990B (zh) * 2021-05-20 2021-07-30 蚂蚁金服（杭州）网络技术有限公司 一种环路检测方法、装置、电子设备与存储介质

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1144688A (en) * 1987-03-17 1988-09-15 Dana-Farber Cancer Institute, Inc. A pharmaceutical composition comprising cyanine dye
GB9708265D0 (en) * 1997-04-24 1997-06-18 Nycomed Imaging As Contrast agents
DE19947559A1 (de) * 1999-09-24 2001-04-19 Schering Ag Antikörper-Farbstoffkonjugate gegen Zielstrukturen der Angiogenese zur intraoperativen Tumorranddarstellung
US6180086B1 (en) * 2000-01-18 2001-01-30 Mallinckrodt Inc. Hydrophilic cyanine dyes
JP2003524018A (ja) * 2000-02-24 2003-08-12 アイトゲネーシシェ テクニシェ ホッホシューレ チューリッヒ フィブロネクチンのｅｄ‐ｂドメインに特異的な抗体、前記抗体を含む複合体、および血管形成を検出および治療するためのその使用
IL162201A0 (en) * 2002-01-03 2005-11-20 Schering Ag New methods for diagnosis and treatment of tumours
WO2003076469A2 (en) * 2002-03-11 2003-09-18 Philogen S.P.A. Antibodies derived rom anti ed-b l19 and targeting tumor vasculature
EP1585791B1 (de) * 2003-01-24 2008-09-24 Bayer Schering Pharma Aktiengesellschaft Hydrophile, thiolreaktive cyaninfarbstoffe und deren konjugate mit biomolekülen für fluoreszenzdiagnose
WO2006073314A1 (en) * 2005-01-06 2006-07-13 Ge Healthcare As Optical imaging
EP1679082A1 (de) * 2005-01-07 2006-07-12 Schering AG Benutzung von Cyaninfarbstoffen für die Diagnose von proliferierenden Krankheiten

Also Published As

Publication number Publication date
AR050264A1 (es) 2006-10-11
PA8640201A1 (es) 2006-07-03
EP1619501B1 (de) 2007-09-26
WO2006008179A3 (en) 2007-01-11
ATE374367T1 (de) 2007-10-15
EP1619501A1 (de) 2006-01-25
WO2006008179A2 (en) 2006-01-26
EP1784226A2 (de) 2007-05-16
AU2005263638A1 (en) 2006-01-26
CA2573783A1 (en) 2006-01-26
UY29029A1 (es) 2005-12-30
CN101022835A (zh) 2007-08-22
EP1816475A1 (de) 2007-08-08
PE20060558A1 (es) 2006-07-26
JP2008506747A (ja) 2008-03-06
TW200613733A (en) 2006-05-01
KR20070062973A (ko) 2007-06-18
SV2006002172A (es) 2006-02-15

Similar Documents

Publication Publication Date Title
DE602004009169D1 (de) Verwendung von Cyanin-farbstoffen zur Diagnose von Krankheiten, welche mit Angiogenese assoziert sind
IL182499A0 (en) Use of cyanine dyes for the diagnosis of proliferative diseases
ATE375518T1 (de) Diagnoseverfahren für erkrankungen unter verwendung von copeptin
DE602005020209D1 (de) System zur Evaluierung von Herzstörungen
LTPA2017011I1 (lt) Antikūnas prieš PDGFR-alfa, skirtas naudoti auglių gydymui
DE602006010132D1 (de) Zwischenprodukte für die Herstellung von Trans-5-Chlor-2-Methyl-2,3,3a,12b-Tetrahydro-1h-DibenzÄ2,3:6,7ÜOxepinoÄ4,5-cÜPyrrol
BRPI0617479A2 (pt) método e composição útil para manter ou melhorar a saúde gastrintestiinal de um animal, kit, meio para comunicação de informações ou instruções, e, uso de uma composição
DE602006009684D1 (de) Zwischenwirbelimplantat für das lumbosakralgelenk
DK1597282T3 (da) Antistofmolekyler, der har specificitet for human IL-1 beta
DE602005020730D1 (de) Fahrzeugradaufhängung
DE602005014723D1 (de) Blutentnahmeset mit vergrössertem Innenvolumen
ATE526307T1 (de) Hydroxybiphenyl-carbonsäuren und derivate, verfahren zu deren herstellung und deren verwendung
DE602006016245D1 (de) Fahrzeug und steuerverfahren für das fahrzeug
ATE550646T1 (de) Füllmaterial für eine mikro-adsorptionssäule zum trocknen und/oder reinigen von gelösten, organischen bzw. biologischen analyten sowie mikro-adsorptionssäule und verwendung derselben
DE602005004393D1 (de) Verfahren zur asymmetrischen hydrierung, das sich für die herstellung von cycloalkanindolderivaten eignet
ATE507222T1 (de) 1,1-dioxo-thiomorpholinyl-indolyl-methanon- derivate zur verwendung als h3-modulatoren
EP1870710A4 (de) Biomarker zur diagnose einer herzerkrankung sowie verwendung davon
DE502006002680D1 (de) Verfahren zur herstellung von feinteiligem c.i. pigment red 254
DE502006004524D1 (de) Verfahren zur herstellung von 3,7-diaza-bicycloä3.3.1ünonan-verbindungen
DE602006016258D1 (de) 4h-1,2,4-triazin-5-on-derivate, ihre herstellung und ihre verwendung als alpha-7-nikotin-acetylcholin-rezeptoren
DE502004007188D1 (de) Für pharmazeutische Verwendung dienende Überkappe mit Verschlussstopfen
DE602005017152D1 (de) Neue 2,6-diaminopyridin-3-on-derivate
FI20041642A0 (fi) Jarrukatkoja
ITVR20050083A1 (it) Telaio ripiegabile, particolarmente per passeggini, carrozzine o simili.
DE112005003466A5 (de) Verfahren zum Nachweis von Herzerkrankungen

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: BAYER SCHERING PHARMA AKIENGESELLSCHAFT, 13353, DE

8332 No legal effect for de